Prior to the spin-off of its biopharma unit into new company Baxalta, Baxter International Inc. said it agreed to buy two drugs to treat a rare form of blood cancer from Sigma-Tau Finanziaria S.p.A. for $900 million. The company announced that it has signed a definitive agreement to acquire the …